1Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co Ltd, Shizuoka, Japan.
Selective adenosine A2A antagonists like KW-6002 increase locomotor activity in Parkinson's disease models. Adenosine A2A receptor agonists reversed this effect, suggesting A2A receptors are a key therapeutic target for Parkinson's disease.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: